Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2020-10-30 AGM Information
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Proxy Statement for the 2020 Annual General Meeting of Shareholders to be held on December 10, 2020
AGM Information Classification · 1% confidence The document is explicitly titled as a 'FORM 6-K' filed with the SEC. The exhibits attached to this Form 6-K are '99.1 Notice and Proxy Statement for the 2020 Annual General Meeting of Shareholders' and '99.2 Form of Proxy Card'. The main body of the text is the 'NOTICE OF 2020 ANNUAL GENERAL MEETING OF SHAREHOLDERS' and the 'PROXY STATEMENT' for that meeting. Since the core content relates directly to soliciting shareholder votes for an Annual General Meeting (AGM) via a proxy statement, the most specific classification is AGM-R (AGM Information). Although it is filed on a Form 6-K, the *purpose* and *content* are overwhelmingly related to the AGM materials.
2020-10-30 English
Proxy Statement for the 2020 Annual General Meeting of Shareholders to be held on December 10, 2020
AGM Information Classification · 1% confidence The document explicitly states: "Notice and Proxy Statement for the 2020 Annual General Meeting of Shareholders to be held on December 10, 2020". This content directly relates to materials provided to shareholders to inform them and solicit their votes for the Annual General Meeting (AGM). This aligns perfectly with the definition for Proxy Solicitation & Information Statement (PSI). Although it mentions the AGM, the core document type described is the Notice and Proxy Statement, which is the primary function of a PSI filing, rather than the AGM presentation itself (AGM-R) or the voting results (DVA). Given the title, PSI is the most accurate classification.
2020-10-30 English
Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021
Regulatory Filings Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed "For the Month of October 2020" by a Foreign Private Issuer (Kamada Ltd.). Form 6-K is a general report required by the SEC for foreign private issuers to report material information not otherwise reported on a regular basis. The content attached as Exhibit 99.1 is a press release announcing a significant business event (a supply agreement with the Israeli Ministry of Health for a COVID-19 treatment) and financial expectations. Since Form 6-K is a catch-all regulatory filing for foreign private issuers that doesn't map directly to 10-K, 10-Q, or proxy statements, and the primary content is a business announcement, it falls under the general category for miscellaneous regulatory filings that do not fit specific definitions. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a Form 6-K, as it is a mandatory SEC filing that doesn't align with the specific content types like ER, CT, or AR.
2020-10-19 English
Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021
Regulatory Filings Classification · 1% confidence The document is very short (2071 characters) and explicitly states it is an 'Immediate Report' under Israeli regulations. Crucially, it contains the phrase: 'Attached hereto is a report on *Kamada Announces Supply Agreement...*'. This structure—a brief announcement referencing an attached or linked document—fits the definition of a Report Publication Announcement (RPA) rather than the full report itself (like ER or CT). Since it is a regulatory filing announcing the availability of information, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule.
2020-10-19 English
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
Regulatory Filings Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed "For the Month of October 2020" by a Foreign Private Issuer (Kamada Ltd.). Form 6-K is a general reporting requirement for foreign private issuers, often used to file material information that is not required to be filed on a Form 20-F. The content attached as Exhibit 99.1 is an announcement titled "Kamada Provides Update on 2021 GLASSIA® Supply to Takeda," which details revenue expectations, supply agreements, and financial guidance updates. This type of material, non-periodic disclosure by a foreign private issuer, is typically filed on Form 6-K. Since the provided definitions do not have a specific code for Form 6-K, and the content is a material business update/press release filed via a regulatory mechanism, the most appropriate general category is 'Regulatory Filings' (RNS), as it serves as a catch-all for required regulatory submissions that don't fit the other specific categories (like 10-K, ER, or DIV). However, given the nature of the content (a business update/press release filed on a specific SEC form), it is a regulatory filing. If the content were purely an Earnings Release (ER) or Management Discussion (MDA), those might apply, but the structure is that of a Form 6-K submission containing an exhibit that functions as a press release. Since RNS is the fallback for miscellaneous regulatory filings, it is the best fit among the provided options for a Form 6-K submission.
2020-10-07 English
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
Report Publication Announcement Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The key phrase is 'Attached hereto is a report on*Kamada Provides Update on 2021 GLASSIA� Supply to Takeda* *ea127902-6k_kamadaltdEDGAR1_Bannerless_isa.pdf*'. This structure indicates that the current document is an announcement *about* another report, rather than the full report itself. Given the short length (1836 chars) and the explicit statement that a report is attached, this fits the definition of a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because it specifically announces the publication of a substantive update.
2020-10-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.